tradingkey.logo

Takeda Announces U.S. FDA Approval Of Gammagard Liquid Erc, The Only Ready-To-Use Liquid Immunoglobulin Therapy With Low Immunoglobulin A (Iga) Content1

ReutersJun 30, 2025 12:17 PM

Takeda Pharmaceutical Co Ltd 4502.T:

  • TAKEDA ANNOUNCES U.S. FDA APPROVAL OF GAMMAGARD LIQUID ERC, THE ONLY READY-TO-USE LIQUID IMMUNOGLOBULIN THERAPY WITH LOW IMMUNOGLOBULIN A (IGA) CONTENT1

  • TAKEDA PHARMACEUTICAL CO LTD - TO DISCONTINUE FIRST-GENERATION LOW-IGA PRODUCT

  • TAKEDA PHARMACEUTICAL CO LTD - GAMMAGARD LIQUID ERC U.S. COMMERCIALIZATION PROJECTED FOR 2026

  • TAKEDA PHARMACEUTICAL CO LTD - GAMMAGARD S/D MANUFACTURING TO BE DISCONTINUED END OF DECEMBER 2027

  • TAKEDA PHARMACEUTICAL CO LTD - TO MAINTAIN GAMMAGARD S/D INVENTORY UNTIL DEPLETED OR EXPIRED

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI